# PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma

> **NCT03226249** · PHASE2 · UNKNOWN · sponsor: **Northwestern University** · enrollment: 30 (actual)

## Conditions studied

- Classical Hodgkin Lymphoma
- Lymphocyte-Depleted Classical Hodgkin Lymphoma
- Lymphocyte-Rich Classical Hodgkin Lymphoma
- Mixed Cellularity Classical Hodgkin Lymphoma
- Nodular Sclerosis Classical Hodgkin Lymphoma

## Interventions

- **PROCEDURE:** Computed Tomography
- **DRUG:** Dacarbazine
- **DRUG:** Doxorubicin Hydrochloride
- **RADIATION:** Fludeoxyglucose F-18
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Pembrolizumab
- **PROCEDURE:** Positron Emission Tomography
- **DRUG:** Vinblastine Sulfate

## Key facts

- **NCT ID:** NCT03226249
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-11-09
- **Primary completion:** 2019-05-17
- **Final completion:** 2024-10
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-06-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03226249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03226249, "PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03226249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*